Advertisement

Retrovirology

, 11:P3 | Cite as

Clinical manifestations in HTLV-1 infected individuals without HAM/TSP: Results of an 8 years cohort

  • Davi Tanajura
  • Néviton Castro
  • Paulo Oliveira
  • Glória Orge
  • Anselmo Souza
  • Natália Barbosa
  • Silvane Santos
  • Edgar Carvalho
Open Access
Poster presentation

Keywords

Incidence Rate Clinical Manifestation Neurological Symptom Asymptomatic Patient Significant Risk Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Introduction

HTLV-1 is an endemic virus in the northeast of Brazil and is related to HAM/TSP in up to 5% of infected individuals. Despite this low prevalence it is known that a higher number of carriers presents with clinical and neurological symptoms that can be sensory, motor, urinary, inflammatory or autonomic.

Method

This is a cohort study with 440 HTLV-1 infected individuals in Salvador, Bahia. Symptoms were computed every year and incidence rates were calculated to each variable in data.

Results

Applying international criteria 163 individuals had definite, possible or probable HAM/TSP and 266 were asymptomatic. The last was selected for analysis. Follow-up of at least one year was archived in 64 to 75% of patients, varying according to the studied variable. The symptoms incidence rate was 20.6% for hand numbness, 18.6% for feet numbness, 12.9% for nocturia, 12.6% for urgency and 13.3% for dry mouth. In the physical exam the incidence was 22.7% for gingivitis, 7.6% for legs hyperreflexia, 5.2% for legs paraparesis and 3.6% for Babinski sign. In annual applied EDSS scale the incidence rate of worsening 1 point was 13.4%. Cox regression was done with EDSS curves and identified proviral load and female gender as significant risk factors (ORs 3.36 [1-11.66] and 1.80 [1.09-2.97] respectively). Six patients developed HAM/TSP during the cohort.

Conclusion

Developing of neurological symptoms or signs occurred in up to 30% of asymptomatic patients during 8 years follow-up. The estimated incidence was 12% for overactive bladder syndrome and 2.25% for definite HAM/TSP.

Copyright information

© Tanajura et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Davi Tanajura
    • 1
  • Néviton Castro
    • 1
  • Paulo Oliveira
    • 1
  • Glória Orge
    • 1
  • Anselmo Souza
    • 1
  • Natália Barbosa
    • 1
  • Silvane Santos
    • 1
  • Edgar Carvalho
    • 1
  1. 1.Immunology DepartmentUniversidade Federal da Bahia (UFBA)SalvadorBrazil

Personalised recommendations